CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $85.7 million in its fourth quarter.
The Cambridge, Massachusetts-based company said it had a loss of $1.53 per share.
The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.57 per share.
The cancer drug developer posted revenue of $34.1 million in the period, falling short of Street forecasts. Eight analysts surveyed by Zacks expected $34.5 million.
For the year, the company reported net income of $313.9 million, or $5.59 per share, swinging to a profit in the period. Revenue was reported as $793.7 million.
Blueprint Medicines shares have declined 17% since the beginning of the year. The stock has increased 46% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC
Please read our comment policy before commenting.